Haima Therapeutics

Haima Therapeutics is pioneering a synthetic platelet technology platform to address critical unmet needs in hemostasis. The company's lead product, SynthoPlate, is an IV-injectable hemostatic agent designed for use in trauma, surgery, and thrombocytopenia, aiming to overcome the severe limitations of donor-derived platelets. By utilizing a fully synthetic, tunable nanoparticle system, Haima seeks to create stable, portable, and universally compatible therapies that can be deployed from the battlefield to the clinic. The platform's versatility also suggests potential applications beyond bleeding, including thrombosis, inflammation, and cancer.

A synthetic nanoparticle platform engineered to mimic platelet functions, including site-specific adhesion/aggregation and targeted bioactive cargo delivery. It is tunable, synthetic, scalable, portable, and designed to be universally compatible.

Competition includes donor platelets (standard of care), other hemostatic agents (e.g., fibrin sealants, recombinant factor VIIa), and a small number of other companies developing platelet-derived or synthetic hemostatic technologies. Haima differentiates with a fully synthetic, tunable, and portable nanoparticle platform.